On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements

  • Lexaria has multiple studies planned that will commence early in 2022
  • DehydraTECH increases Lexaria’s ability to leverage multiple markets, including the growing CBD sector, which is expected to meet and exceed $108 billion in revenue by 2027
  • DehydraTECH can increase the efficacy of the drugs being administered, offering faster absorption and lowering the delivery time

In a strategic move to start off 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that it has signed an advertising and media contract with financial technology company SRAX (NASDAQ: SRAX). The contract will facilitate media buys and digital marketing by SRAX on behalf of Lexaria. This announcement is only the beginning of what the company anticipates to be the busiest year yet.

Chris Bunka, CEO of Lexaria, was more than pleased with the contract signed and with SRAX, and he voiced optimism about the year-long campaign that has commenced and its outcomes. “Lexaria has made tremendous progress during 2021, and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria’s achievements are communicated to all investors,” Bunka added (https://ibn.fm/00Ed4).

Lexaria’s patented DehydraTECH(TM) was designed for orally delivered fat-soluble drugs and other active pharmaceutical ingredients and this technology has shown it increases effectiveness and improves absorption into the bloodstream. Through this technology, Lexaria demonstrates many benefits:  efficiently reduces delivery time to bloodstream and thus shortens the time it takes for these drugs to take effect; increases brain absorption; reduces the costs required for drug administration through smaller doses; increases the level of drug in the bloodstream for greater effectiveness; and masks the unpleasant tastes of many oral drugs.

After the progress that Lexaria made in 2021, the company has several projects lined up to be initiated and conducted throughout the new year. Lexaria already has planned:

  • A human clinical trial over the duration of six weeks to study hypertension and how Lexaria’s DehydraTECH-CBD (cannabidiol) may provide potential hypertension relief
  • An oral nicotine human study (which may be industry-changing) that includes subjective and objective parameters to demonstrate the superiority of DehydraTECH-nicotine as compared to the industry’s leading product
  • Animal studies that are designed to determine if DehydraTECH-CBD can provide seizure relief and compare it against the current FDA-approved pharmaceutical regimen for treatment against seizures
  • Completion of the company’s pre-IND meeting with FDA so that they may proceed with the IND application process – registering the clinical trial testing that will be conducted with DehydraTECH-CBD for hypertension relief

Lexaria has the potential to leverage more than one expanding pharmaceutical market using the company’s patented DehydraTECH technology. These markets include but are not limited to  CBD, oral nicotine, and other fat-soluble molecularly structured drugs. The CBD market alone is rapidly growing, providing multiple opportunities for innovation and investment. The market was worth over $7.1 billion in 2020 and is expected to grow at a CAGR of 35% to exceed $108 billion by 2027 (https://ibn.fm/v2d5w). The drivers for growth in this industry include the rising interest in medical applications using CBD, product adoption and utilization with government approval, the continually changing regulatory landscape for CBD products, and the increase of retail sales. Lexaria is a global leader in CBD research.

Another market Lexaria has the potential to tap into is the global antihypertensive therapeutics sector. According to Allied Market Research, the global antihypertensive drugs market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, expanding at a CAGR of 3.1% (https://ibn.fm/lDt5j).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered